Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Compare the progression-free survival (PFS) of treatment-naïve patients with mRCC receiving AG-013736 vs sorafenib. Estimate the progression-free survival (PFS) of previously-treated Asian patients with mRCC receiving AG-013736 vs sorafenib.
Critère d'inclusion
- metastatic renal cell cancer